Terumo (OTCMKTS:TRUMY) Upgraded at Nomura

Nomura upgraded shares of Terumo (OTCMKTS:TRUMY) to a hold rating in a report released on Tuesday,Zacks.com reports.

Terumo Stock Down 0.8%

TRUMY stock opened at $13.08 on Tuesday. The stock’s 50 day simple moving average is $13.81 and its 200 day simple moving average is $15.62. The company has a market cap of $19.29 billion, a P/E ratio of 22.55 and a beta of 0.74. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.46 and a current ratio of 2.51. Terumo has a fifty-two week low of $12.15 and a fifty-two week high of $20.12.

Terumo (OTCMKTS:TRUMY) last announced its quarterly earnings data on Friday, February 13th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Terumo had a net margin of 11.74% and a return on equity of 9.13%. The firm had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.82 billion.

Terumo Company Profile

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.